Preclinical Data from Assembly Biosciences’ Immuno-Oncology Microbiome Program Featured at AACR’s Virtual Annual Meeting II
“There is growing evidence supporting the role of gut commensal microbes in mediating patient responses to immune checkpoint inhibitor therapies, which provides a rationale for a live microbial biotherapeutic product (LBP) approach,” said
Assembly’s program for oncology discovers and develops defined consortia of bacteria, rationally selected based on disease-relevant immunological mechanisms, that can be encapsulated, orally administered and delivered to the gastrointestinal tract of cancer patients. As described in the poster, the research team established a biological function-based platform to identify bacterial strains with immune stimulatory activities in vitro and significant anti-tumor efficacy alone or in combination with checkpoint antibody in syngeneic tumor models:
- Commensal microbes were isolated from well-characterized healthy human samples
- Reproducible, tumor immunology-relevant functional activities demonstrated in validated cell-based assays
- e.g. production of immune-stimulatory cytokines by human PBMC or DC, T cell activation, M1 macrophage shift
- Reproducible anti-tumor activity of strains & consortia in syngeneic mouse tumor models
- Defined consortia significantly enhance checkpoint antibody efficacy
- Immunophenotyping data supports mechanisms of interest including increase in inflammatory cytokines and immune cell infiltration in the tumor
About Assembly Biosciences’ Microbiome Platform
From concept to clinic, Assembly has developed an integrated live biotherapeutic product (LBP) program from discovery through manufacturing and ultimately into the clinic that features a biological function-based discovery strategy, creating a broad-based platform that is capable of addressing multiple therapeutic indications. Individual bacteria and consortia are selected for development based on a platform of in silico, in vitro and in vivo capabilities. The biologic drug candidates are manufactured under scalable GMP conditions. Assembly’s in-house, end-to-end capabilities also include its licensed patented Gemicel® capsule-in-capsule delivery system designed for targeted dual release oral delivery to the gastrointestinal tract (GI).
Assembly’s lead live biotherapeutic product candidate, ABI-M201, is being evaluated in a multi-center randomized, double-blind, placebo-controlled Phase 1b trial in patients with mildly to moderately active ulcerative colitis. ABI-M301 is a preclinical program for Crohn’s disease.
About Assembly Biosciences
The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly’s ability to progress development of its oral LBP program in immuno-oncology; and preclinical data on the oral LBP program may not translate into clinical results if and when it advances to the clinic. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Readers are cautioned not to rely on these forward-looking statements. Assembly intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly's filings with the
Assembly Biosciences, Inc. Amy Figueroa, CFA Investor Relations Consultant (415) 366-5158 firstname.lastname@example.org Solebury Trout Luke Brown(646) 378-2944 email@example.com
Source: Assembly Biosciences, Inc.